Date: November 10. Time: 11:00AM EST.
Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens. These biomarkers can have relevance for disease detection, disease progression and relapse over time, and can indicate potential response to treatment for use in the discovery, development and validation of liquid biopsy tests and targeted oncology therapies.
Take the Next Step
1
2
3
Explore Suppliers
Browse trusted partners with relevant expertise
Review Capabilities
Compare services, experience, and past work
Start Your Project
Connect and begin collaborating
.jpg)